Sanofi Reports long-term follow-up Data for Aducanumab in Psoriasis

Sanofi today announced long-term follow-up results for aducanumab in patients with psoriasis. The study demonstrated that aducanumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of psoriasis and support the continued development of aducanumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.